You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Merck
Johnson and Johnson
Express Scripts
Dow

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AIR POLYMER-TYPE A

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Air Polymer-type A

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT04026945 Sustained Release Lidocaine for Treatment of Scrotal Pain Not yet recruiting University of British Columbia Phase 1/Phase 2 2019-07-01 In this study, we are testing a new formulation of lidocaine for its suitability in managing chronic scrotal pain (CSCP). The new formulation ST-CP is a lidocaine sustained-release formulation and is expected to provide pain relief over 4 weeks. Currently, the drug lidocaine is not available as an injectable slow-release formulation and chronic scrotal pain patients are often left untreated.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Air Polymer-type A

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003876 Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma Completed Barrett Cancer Center Phase 1 1999-04-01 RATIONALE: Internal radiation uses high-energy radiation to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining internal radiation therapy with chemotherapy implants may kill remaining tumor cells following surgery. PURPOSE: Phase I trial to study the effectiveness of internal radiation therapy plus carmustine implants in treating patients who have recurrent or refractory malignant glioma.
NCT00003878 Carmustine Implants in Treating Patients With Brain Metastases Completed National Cancer Institute (NCI) Phase 2 2002-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of implanted carmustine wafers in treating patients who have brain metastases and who are undergoing surgery to remove the tumor.
NCT00003878 Carmustine Implants in Treating Patients With Brain Metastases Completed New Approaches to Brain Tumor Therapy Consortium Phase 2 2002-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of implanted carmustine wafers in treating patients who have brain metastases and who are undergoing surgery to remove the tumor.
NCT00004315 Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease Unknown status Children's Hospital Medical Center, Cincinnati Phase 2 1995-11-01 OBJECTIVES: I. Compare the bioavailability of polymer-coated and buffered ursodiol (ursodeoxycholic acid) to unmodified ursodiol in patients with cystic fibrosis-associated liver disease or chronic cholestatic liver disease. II. Compare the differences in pruritus, weight gain, and liver function for both treatments.
NCT00004315 Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease Unknown status National Center for Research Resources (NCRR) Phase 2 1995-11-01 OBJECTIVES: I. Compare the bioavailability of polymer-coated and buffered ursodiol (ursodeoxycholic acid) to unmodified ursodiol in patients with cystic fibrosis-associated liver disease or chronic cholestatic liver disease. II. Compare the differences in pruritus, weight gain, and liver function for both treatments.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Air Polymer-type A

Condition Name

Condition Name for Air Polymer-type A
Intervention Trials
Coronary Artery Disease 6
Acute Coronary Syndrome 4
Metastatic Breast Cancer 4
Stage IV Breast Cancer 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Air Polymer-type A
Intervention Trials
Coronary Artery Disease 9
Myocardial Ischemia 8
Coronary Disease 8
Acute Coronary Syndrome 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Air Polymer-type A

Trials by Country

Trials by Country for Air Polymer-type A
Location Trials
United States 116
Canada 15
Korea, Republic of 8
Russian Federation 6
Thailand 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Air Polymer-type A
Location Trials
California 12
Florida 8
Maryland 8
New York 7
North Carolina 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Air Polymer-type A

Clinical Trial Phase

Clinical Trial Phase for Air Polymer-type A
Clinical Trial Phase Trials
Phase 4 16
Phase 3 10
Phase 2 20
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Air Polymer-type A
Clinical Trial Phase Trials
Completed 38
Recruiting 23
Not yet recruiting 15
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Air Polymer-type A

Sponsor Name

Sponsor Name for Air Polymer-type A
Sponsor Trials
National Cancer Institute (NCI) 9
Norwegian University of Life Sciences 5
Meabco A/S 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Air Polymer-type A
Sponsor Trials
Other 103
Industry 54
NIH 15
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Harvard Business School
Johnson and Johnson
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.